Marinus Pharmaceuticals has been granted a patent for a method of treating status epilepticus (SE) using ganaxolone. The method involves administering an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid to suppress SE for at least 8 hours. The ganaxolone plasma concentration is maintained at a level of at least 500 ng/ml for 8 to 12 hours, with the infusion rate adjusted during this period. The total daily dose of ganaxolone administered is between 500 mg and 900 mg. GlobalData’s report on Marinus Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Marinus Pharmaceuticals, nanoparticle drug conjugates was a key innovation area identified from patents. Marinus Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Method of treating status epilepticus with ganaxolone infusion
A recently granted patent (Publication Number: US11679117B2) describes a method for treating status epilepticus (SE) using ganaxolone. Status epilepticus is a medical emergency characterized by prolonged seizures that can be life-threatening if not promptly treated. The method involves administering ganaxolone to a patient intravenously as an initial bolus followed by a continuous infusion to maintain a plasma concentration of at least 500 ng/ml for a period of 8 to 12 hours.
The patent claims specify various aspects of the method. Claim 1 states that the effective amount of ganaxolone administered should be sufficient to suppress status epilepticus for at least 8 hours, with a plasma concentration of at least 500 ng/ml to 1000 µg/ml. The total daily dose of ganaxolone administered ranges from 500 mg to 900 mg.
Additional claims provide more specific details. For example, claim 3 states that the initial bolus should contain 5 mg to 40 mg of ganaxolone, while claim 5 specifies that the continuous infusion should range from 20 mg to 80 mg of ganaxolone per hour. Claim 11 describes a specific administration protocol, including different infusion rates at different time intervals.
The patent also claims that the method results in a reduction of seizure burden, with claim 23 stating that the reduction can be at least 50% relative to the seizure burden prior to treatment. The reduction in seizure burden is expected to persist for at least 8 to 12 hours.
Overall, this granted patent describes a method for treating status epilepticus using ganaxolone administered intravenously. The method involves an initial bolus followed by a continuous infusion to maintain a specific plasma concentration of ganaxolone. The patent provides specific dosage ranges and administration protocols, as well as claims regarding the reduction of seizure burden.
To know more about GlobalData’s detailed insights on Marinus Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
